A US-based fast growing SMB Pharmaceutical company was determined for obtaining Regulatory approval and commercialization of super generic drugs and biotechnology products in North America, Latin America, and Europe. In addition to client’s requirement for quick deliverables, finding long-term reliable partner in the specific region to take forward ANDA eCTD submissions was an immediate challenge.

Read more to decode how Freyr supported diverse set of services to secure cost benefits and successful completion of ANDA eCTD submission within three weeks